menu
    • menu

    Company profile for Oasmia Pharmaceutical

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology ...
    Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR17.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Oasmia PharmaceuticalSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Vallongatan 1 752 28 Uppsala
    Telephone
    Telephone
    (203) 409-5444
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oasmia.com/en/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/oasmia

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug
    Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug

    22 Mar 2022

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/lonza-signs-manufacturing-agreement-with-oasmia-ovarian-cancer-drug-2022-03-21/

    REUTERS
    22 Mar 2022
    Share Share
    Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal
    Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal

    01 Mar 2021

    // PHARMAFILE

    http://www.pharmafile.com/news/571751/oasmia-acquires-rights-cancer-drug-candidate-cantrixil-44m-deal

    PHARMAFILE
    01 Mar 2021
    Share Share
    Kazia Licenses Cantrixil, a Clinical-stage Ovarian Cancer Drug, to Oasmia
    Kazia Licenses Cantrixil, a Clinical-stage Ovarian Cancer Drug, to Oasmia

    01 Mar 2021

    // PRNASIA

    https://en.prnasia.com/releases/apac/kazia-licenses-cantrixil-a-clinical-stage-first-in-class-ovarian-cancer-drug-candidate-to-oasmia-pharmacetical-ab-310003.shtml

    PRNASIA
    01 Mar 2021
    Share Share
    Oasmia AB Signs Phase 1b Trial Agreement with SAKK, The Swiss Group
    Oasmia AB Signs Phase 1b Trial Agreement with SAKK, The Swiss Group

    08 Jun 2020

    // PRESS RELEASE

    https://www.oasmia.com/en/oasmia-pharmaceutical-ab-signs-phase-1b-trial-agreement-with-sakk-the-swiss-group-for-clinical-cancer-research-for-evaluation-of-docetaxel-micellar/

    PRESS RELEASE
    08 Jun 2020
    Share Share
    Oasmia Pharmaceutical announces poster presentation at ASCO
    Oasmia Pharmaceutical announces poster presentation at ASCO

    14 May 2020

    // PRESS RELEASE

    https://www.oasmia.com/en/oasmia-pharmaceutical-announces-poster-presentation-at-american-society-of-clinical-oncology-2020-annual-meeting/

    PRESS RELEASE
    14 May 2020
    Share Share
    Oasmia announces outcome of review to deliver long-term, profitable growth
    Oasmia announces outcome of review to deliver long-term, profitable growth

    13 May 2020

    // PRESS RELEASE

    https://www.oasmia.com/en/oasmia-announces-outcome-of-strategic-review-to-deliver-long-term-profitable-growth-as-a-specialty-pharma-company/

    PRESS RELEASE
    13 May 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search